CN1135227C - 除草的2,6-二取代吡啶和2,4-二取代嘧啶 - Google Patents
除草的2,6-二取代吡啶和2,4-二取代嘧啶 Download PDFInfo
- Publication number
- CN1135227C CN1135227C CNB961025476A CN96102547A CN1135227C CN 1135227 C CN1135227 C CN 1135227C CN B961025476 A CNB961025476 A CN B961025476A CN 96102547 A CN96102547 A CN 96102547A CN 1135227 C CN1135227 C CN 1135227C
- Authority
- CN
- China
- Prior art keywords
- methyl
- pyrimidine
- trifluoromethyl
- oxygen base
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
- A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
- A01N43/54—1,3-Diazines; Hydrogenated 1,3-diazines
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
- A01N43/56—1,2-Diazoles; Hydrogenated 1,2-diazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
- C07D213/643—2-Phenoxypyridines; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/68—One oxygen atom attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/69—Two or more oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
- C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Dentistry (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Agronomy & Crop Science (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Plural Heterocyclic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Pyridine Compounds (AREA)
Abstract
本发明涉及新颖的通式(I)的吡啶和嘧啶衍生物。其中,A表示任意取代的芳基或任意取代的5元或6元含氮芳杂基或二氟苯并间二氧杂环戊烯基;m表示0-5的整数;n表示0-2的整数;R1(或每个R1)各自表示氢原子、卤原子、任意取代的烷基等;R2(或每个R2)各自表示氢原子、卤原子、任意取代的烷基等;X表示氧或硫原子;和Z表示氮原子或CH基团;R2m另有附加条件。它们可用常规方法制备,特别可用作除草剂。
Description
本发明涉及特定的2,6-二取代吡啶和2,4-二取代嘧啶、它们的制备方法和作为除草剂的用途。
吡啶、嘧啶和它们的衍生物在药学领域及农业(除草剂、杀真菌剂、杀螨剂、驱虫剂、驱鸟剂)方面,聚合物和纺织工业的反应试剂、中间体和化学品方面有许多用途。
例如,(DE 40 29 654和JO 2131-480)已叙述用2-芳基嘧啶和2-嘧啶-6-芳基吡啶作杀真菌剂,EP 263,958涉及2,6-二苯基吡啶除莠剂,EP 354,766和435,247各自揭示了结构相关的2,4-二苯基嘧啶,据称它也是除莠剂。另一个例子是EP 572,093公开的作为除莠剂的2,6-二苯氧基吡啶。在DE 29 35 578中揭示的4-苯氧基-2-吡唑-1-基-嘧啶有杀真菌活性。Huelsen(Diplomarbeit,Konstanz1993年)揭示了四种不同的2-(1-甲基-3-三氟甲基-吡唑-5-基氧基)-6-苯基吡啶,但是它们没有生物活性。
令人惊奇的是,现已发现在有芳基和芳氧基或杂芳氧基的相关、新颖的吡啶和嘧啶衍生物中存在良好的除莠活性。这些化合物出人意料地显示了在芽前和芽后施用时对阔叶和草叶杂草的优秀活性和良好的作物选择性。
因此,本发明提供了下列通式的2,6-二取代吡啶和2,4-二取代嘧啶:其中A表示任意取代的芳基或任意取代的5元或6元含氮芳杂基或二氟苯并间二氧杂环戊烯基;m表示0-5的整数;n表示0-2的整数;R1(或每个R1)各自表示氢原子、卤原子、任意取代的烷基、链烯基、炔基、烷氧基、烷氧基烷基、二烷氧基烷基、烷氧基烷氧基、烷硫基、氨基、烷氨基、二烷氨基、烷氧基氨基或亚胺甲基氨基;R2(或每个R2)各自表示氢原子、卤原子、任意取代的烷基、链烯基炔基、卤代烷基、卤代烷氧基、烷氧基、烷氧基烷氧基、烷硫基或硝基、氰基、SF5或烷基磺酰基或烷基亚磺基;X表示氧或硫原子;和Z表示氮原子或CH基团;附加条件是若A表示1-甲基-3-三氟甲基-吡唑-5-基,n为0,X表示氧原子,和Z表示CH基团,则R2m不是氢或3-三氟甲基或2,4-二氯或2,4-二甲基。
作为取代基或其它取代基中的一部分的芳基或A定义中的芳基,合适的是任意取代的苯基或萘基。在A定义中5-或6-元芳杂基包括含一个或多个氮原子和/或氧和/或硫原子的任意取代的5元或6元杂环,较好地有1-3个氮原子。这类基团的例子是吡唑基、咪唑基、三唑基、四唑基、吡啶基、吡嗪基、嘧啶基、哒嗪基、异噁唑基、异噻唑基和三嗪基。就A而论“芳基″的定义也包括由苯环和上述定义的5元或6元芳杂环稠合构成的二元环系,同样也包括5元或6元杂环可与苯环稠合构成的二元环系。A的另一个较好例子是下式的二氟苯并间二氧杂环戊烯:
一般来说,除非另有说明,若上述的任何部分包括烷基、链烯基或炔基,则这类基团可为含1-12个碳原子,较好地含1-4个碳原子的直链或支链。这类基团的例子是甲基、乙基、丙基、乙烯基、烯丙基、异丙基、丁基、异丁基和叔丁基。卤代烷基、卤代烷氧基、烷硫基或烷氧基的合适的烷基部分有1-4个碳原子,较好的有1或2个碳原子。烷氧基烷基、烷氧基烷氧基或二烷氧基烷基中的烷基部分的碳原子数最多为6,较好的是最多为4,如,甲氧基甲基、甲氧基甲氧基、甲氧基乙基、乙氧基甲基、乙氧基乙氧基、二甲氧基甲基。
“卤素”指氟、氯、溴或碘原子,较好的是氟、氯或溴。卤代烷基和卤代烷氧基较好的是一-、二-或三氟烷基和-烷氧基,特别是三氟甲基和三氟甲氧基。
当基团为任意取代时,任意存在的取代基可以是杀虫剂化合物改性和/或开发中习惯使用的任何取代基,特别是可保持或增加与本发明化合物有关的除莠活性的取代基,或对作用的持久性、对土壤、植物的渗透性或任何这类除莠化合物的其它所需性质有影响的取代基。在分子中的每个部分可以有一个或多个相同或不同取代基。涉及上述定义的任意取代的烷基部分,它包括卤代烷基、烷氧基烷硫基、卤代烷氧基、烷氨基和二烷氨基的烷基部分,这类取代基的具体例子包括苯基、卤原子、硝基、氰基、羟基、C1-4烷氧基、C1-4卤代烷氧基和C1-4烷氧基羰基。
关于上述定义的任意取代的芳基或芳杂基部分,任意的取代基包括卤素,特别是氟氯和溴原子和硝基、氰基、氨基、羟基、C1-4烷基、C1-4烷氧基、C1-4卤代烷基和C1-4卤代烷氧基和诸如SF5的卤代硫烷基(halosulfanyl)。合适的可有1-5个取代基,较好的有是1-2个取代基。典型的卤代烷基、卤代烷氧基和卤代烷硫基是三氟甲基、三氟甲氧基和三氟甲硫基基。
m优选的表示1-3整数的,n优选的是1(此时R1不是氢原子)。
通式I的化合物是油状、胶状或大部分是结晶固体物质。它们可用于农业或用于通过芽前或芽后施用抑制诸如看麦娘,稗,狗尾草,猪秧秧,繁缕,灯笼婆婆纳,野芝麻,堇菜,苘麻,圆叶牵牛和反枝苋的不需要的植物的相关领域。本发明通式I的化合物在宽浓度范围里具有高的除草活性,可用于农业。
优选的化合物是式中A表示被一个或多个选自卤原子、烷基、烷氧基、卤代烷基、卤代烷氧基和五卤代硫烷基的相同或不同取代基取代的苯基、吡啶基或吡唑基。
特别优选的是基团A中在该基团连接点的间位有取代基的化合物。
当A在间位被氯原子或三氟甲基取代时,特别A是2-氯吡啶-4-基、1-甲基-3-三氟甲基吡唑-5-基或3-三氟甲基苯基时,得到对不需要植物控制的良好结果。
当用式中X表示氧原子的化合物时得到控制杂草的特别好的结果。
在该式中A表示3-三氟甲基苯基、2-氯代吡啶-4-基、2-三氟甲基吡啶-4-基、2-二氟甲氧基吡啶-4-基或1-甲基-3-三氟甲基吡唑-5-基。R1的定义同上;R2,R2′和R2″各自代表氢原子、氟、氯或溴原子,它们中的一个或两个为三氟甲基、三氟甲氧基或氰基,R2′可进一步为C1-C4烷基,特别是叔丁基。
本发明化合物列举如下:
2-(1′-甲基-3′-三氟甲基吡唑-5-基氧基)-6-(4″-三氟甲基苯基)吡啶,
2-(2′,4′-二氟苯基)-6-甲基-4-(1″-甲基-3″-三氟甲基嘧唑-5-基氧基)嘧啶,
2-(2′,4′-二氟苯基)-6-甲基-4-(3″-三氟甲基苯氧基)嘧啶,
2-(2′-氯吡啶-4′-基氧基)-(4″-三氟甲基苯基)吡啶,
2-(2′-氯吡啶-4′-基氧基)-6-(3″-三氟甲基苯基)吡啶,
2-(3′-氯苯基)-5-甲基-4-(1″-甲基-3″-三氟甲基吡唑-5-基氧基)嘧啶,
2-(3′-氯苯基)-5-甲基-4-(3″-三氟甲基苯氧基)嘧啶,
2-(4′-氟苯基)-6-甲基-4-(3″-三氟甲基苯氧基)嘧啶,
2-(4′-氟苯基)-4-(1″-甲基-3″-三氟甲基吡唑-5-基氧基)-5-甲基嘧啶,
2-(4′-氟苯基)-4-(1″-甲基-3″-三氟甲基吡唑-5-基氧基)-6-甲基嘧啶,
4-(2″-氯吡啶-4″-基氧基)-2-(2′,4′-二氟苯基)-5-甲基嘧啶,
4-(2″-氯吡啶-4″-基氧基)-5,6-二甲基-2-(4′-三氟甲氧基苯基)嘧啶,
4-(2″-氯吡啶-4″-基氧基)-5,6-二甲基-2-(4′-三氟甲基苯基)嘧啶,
4-(2″-氯吡啶-4″-基氧基)-5-甲基-2-(4′-三氟甲氧基苯基)嘧啶,
4-(2″-氯吡啶-4″-基氧基)-5-甲基-2-(4′-三氟甲基苯基)嘧啶,
4-(2″-氯吡啶-4″-基氧基)-6-甲基-2-(4′-三氟甲氧基苯基)嘧啶,
4-(2″-氯吡啶-4″-基氧基)-6-甲基-2-(4′-三氟甲基苯基)嘧啶,
5-乙基-6-(4″-三氟甲基苯基)-2-(3′-三氟甲基苯基)吡啶,
4-甲基-6-(4″-三氟甲氧基苯基)-2-(1′-甲基-3′-三氟甲基吡唑-5′基氧基)吡啶,
4-甲基-6-(4″-三氟甲氧基苯基)-2-(2′-氯吡啶-4′-基氧基)吡啶,
4-甲基-6-(4″-三氟甲基苯基)-2-(1′-甲基-3′-三氟甲基吡唑-4′-基氧基)吡啶,
4-甲基-6-(4″-三氟甲基苯基)-2-(2′-氯吡啶-4′-基氧基)吡啶,
4-甲基-6-(4″-三氟甲基苯基)-2-(2′-氯吡啶-4′-基氧基)吡啶,
4-甲基-6-(4″-氟苯基)-2-(1′-甲基-3′-三氟甲基吡唑-5′-基氧基)吡啶,
5,6-二甲基-2-(4′-三氟甲氧基苯基)-4-(1″-甲基-3″-三氟甲基吡唑-5″-基氧基)嘧啶,
5,6-二甲基-2-(4′-三氟甲氧基苯基)-4-(3″-三氟甲基苯氧基)嘧啶,
5,6-二甲基-2-(4′-三氟甲基苯基)-4-(3″-三氟甲基苯氧基)嘧啶,
5,6-二甲基-4-(1″-甲基-3″-三氟甲基吡唑-5″-基氧基)-2-(4′-三氟甲基苯基)嘧啶,
5-甲基-2-(3′-甲基苯基)-4-(1″-甲基-3″-三氟甲基吡唑-5″-基氧基)嘧啶,
5-甲基-2-(3′-甲基苯基)-4-(3″-三氟甲基苯氧基)嘧啶,
5-甲基-2-(4′-三氟甲氧基苯基)-4-(1″-甲基-3″-三氟甲基吡唑-5″-基氧基)嘧啶,
5-甲基-2-(4′-三氟甲氧基苯基)-4-(3″-三氟甲基苯氧基)嘧啶,
5-甲基-2-(4′-三氟甲基苯基)-4-(1″-甲基-3″-三氟甲基吡唑-5″-基氧基)嘧啶,
5-甲基-4-(3″-三氟甲基苯氧基)-2-(4′-三氟甲基苯基)嘧啶,
6-(4″-氟苯基)-2-(1′-甲基-3′-三氟甲基吡唑-5′-基氧基)吡啶,
6-甲基-2-(4′-三氟甲氧基苯基)-4-(1″-甲基-3″-三氟甲基吡唑-5″-基氧基)嘧啶,
6-甲基-2-(4′-三氟甲氧基苯基)-4-(3″-三氟甲基苯氧基)嘧啶,
6-甲基-4-(3″-三氟甲基苯氧基)-2-(4′-三氟甲基苯基)嘧啶,
6-甲基-2-(4′-三氟甲基苯基)-4-(1″-甲基-3″-五氟乙基吡唑-5″-基氧基)嘧啶,
6-甲基-2-(4′-氰基苯基)-4-(1″-甲基-3″-五氟乙基吡唑-5″-基氧基)嘧啶,
6-甲氧基-2-(4′-氰基苯基)-4-(1″-甲基-3″-五氟乙基吡唑-5″-基氧基)嘧啶,
6-甲基-4-(2″,2″-二氟-1″,3″-苯并间二氧杂环戊烯-4″-基)-2-(4′-三氟甲基苯基)嘧啶,
6-乙基-2-(4′-三氟甲基苯基)-4-(1″-甲基-3″-三氟甲基吡唑-5″-基氧基)嘧啶,
6-乙基-2-(4_三氟甲基苯基)-4-(3″-三氟甲基苯氧基)嘧啶,
6-甲基-2-(4′-甲磺酰苯基)-4-(1″-甲基-3″-五氟乙基吡唑-5″基氧基)嘧啶,
6-乙基-2-(4′-三氟甲基苯基)-4-(2′-氯吡啶-4′-基氧基)嘧啶,
6-炔丙基-2-(4′-三氟甲基苯基)-4-(1″-甲基-3″-三氟甲基吡唑-5″-基氧基)嘧啶,
6-甲氧基甲基-2-(4′-氯苯基)-4-(1″-甲基-3″-三氟甲基吡唑-5″-基氧基)嘧啶,
6-甲氧基甲基-2-(4′-氯苯基)-4-(3″-三氟甲基苯氧基)嘧啶,
6-甲氧基甲基-2-(4′-氯苯基)-4-(3″-三氟甲基苯氧基)嘧啶,
4-(3″-三氟甲基苯氧基)-2-(4′-三氟甲基苯基)嘧啶,
4-(1″-甲基-3″-三氟甲基吡唑-5″-基氧基)-2-(4′-三氟甲基苯基)嘧啶,
6-氯-2-(4′-三氟甲基苯基)-4-(1″-甲基-3″-三氟甲基吡唑-5″-基氧基)嘧啶,
6-溴-2-(4′-三氟甲基苯基)-4-(1″-甲基-3″-三氟甲基吡唑-5″-基氧基)嘧啶,
6-氯-2-(4′-氯甲基苯基)-4-(1″-甲基-3″-三氟甲基吡唑-5″-基氧基)嘧啶,
6-氟-2-(4′-三氟甲基苯基)-4-(1″-甲基-3″-三氟甲基吡唑-5″-基氧基)嘧啶,
6-甲氧基-2-(4′-三氟甲基苯基)-4-(3″-三氟甲基苯氧基)嘧啶,
6-甲氧基-2-(4′-三氟甲基苯基)-4-(1″-甲基-3″-三氟甲基吡唑-5″-基氧基)嘧啶,
6-甲氧基-2-(4′-三氟甲基苯基)-4-(2′-氯吡啶-4′-基氧基)嘧啶,
5-甲氧基-2-(4′-三氟甲基苯基)-4-(3″-三氟甲基苯氧基)嘧啶,
5-甲氧基-2-(4′-三氟甲基苯基)-4-(1″-甲基-3″-三氟甲基吡唑-5″-基氧基)嘧啶,
5-甲氧基-2-(4′-三氟甲基苯基)-4-(2′-氯吡啶-4′-基氧基)嘧啶,
6-乙氨基-2-(4′-三氟甲基苯基)-4-(1″-甲基-3″-三氟甲基吡唑-5″-基氧基)嘧啶,
6-甲氧基氨基-2-(4′-氯苯基)-4-(1″-甲基-3″-三氟甲基吡唑-5″-基氧基)嘧啶,
6-乙烯基-2-(4′-三氟甲基苯基)-4-(1″-甲基-3″-三氟甲基吡唑-5″-基氧基)嘧啶。
本发明化合物可用常规方法制得。
卤原子Hal可为任何的卤原子,合适的是用氟、氯或溴原子。金属原子M可为任何金属原子,可用合适的碱金属原子,较好的是钠和钾。
另一方面是,若R1是任意取代的烷氧基、烷氧基烷氧基、烷硫基、氨基、烷基氨基、二烷基氨基或烷氧基氨基时,可使通式XV化合物与R1-H反应,较好的是在碱的存在下进行反应得到通式I化合物。其中A、R2和m的定义同上。
通过使R1-H或它的有机金属衍生物,较好的是在过渡金属催化剂或碱的存在下与式中R1为卤原子,优选的是氯或溴,的化合物I反应可制得其中R1的炔基或链烯基,如烯丙基或炔丙基型的化合物I。
通过使式III化合物与上述约2当量的式IV化合物反应(其中X表示氧)可制得化合物XV,此时,式III中R1是Hal,Z是氮,Hal、R2和m的定义同上。
在实际使用中,反应可在有或无溶剂的存在下进行,这可促进反应或至少不干扰反应。较好的是极性、非质子传递溶剂或质子传递溶剂,适当的是N,N-二甲基甲酰胺或二甲亚砜或环丁砜,或诸如四氢呋喃或二噁烷的醚类或醇类或水或它们的混合物。反应在室温和反应混合物的回流温度间进行,较好的在较高温度,特别是回流温度下进行。
Z表示C-H,n是0的式III化合物可这样制得:根据Org.Syn-thesis Col.Vol.III,305f,在常规的醇类溶剂,优选的是乙醇中使通式V化合物:其中R2和m的定义同上,与醛类,合适的是甲醛,和二烷胺,合适的是二甲胺,反应得到通式VI化合物:再根据DBP 21 47 288(1971)接着与铵盐,合适的是乙酸铵,和通式VII化合物在溶剂中,合适的是醇类,优选的是乙醇中反应,其中Y是烷氧基或NH2基团,优选的是乙氧基,得到通式VIII化合物。通过使VIII与磷酰卤,优选的是磷酰溴或磷酰氯在较高的温度下,理想的是回流温度下反应(Muller,E.,Chem.Ber.42,423(1909);Katrizky等,J.Chem.Soc.,Perkin Trans.第一部分,1980,2743-2754)进一步转化得到通式III化合物。
制备通式III中Z表示C-H基团的化合物的较好的另一方法包括使通式IX的2,6-二卤代吡啶其中R1和n的定义同上,Hal1和Hal2各自代表卤原子,与大致等摩尔比的通式(X)的有机金属苯衍生物,任意地在过渡金属催化剂的存在下反应其中R2和m的定义同上,M表示碱金属原子或烃基硼或锡或镁或锌或铜。
碱金属可为任何碱金属,优选的是锂,反应可在非质子传递、极性溶剂中,优选的在醚中进行,得到通式III的化合物,这在Cook和Wakefield,J.Chem.Soc.,1969,2376中论及,或在非极性溶剂或水中进行,例如Ali,N.M.等,Tetrahedron 1992,8117中所述的例子。
可根据Gungor,T Marsais,F和Queguiner,G在J.Organometallic Chem.,1981,139-150中所述的相似方法将式III中Z表示CH,Hal是氟,R1是氢,R2和m的定义同上的化合物进一步转化为n=1、Z表示CH、Hal是氟、R2、m的定义同上,R1处于3位并表示甲硫基(或选自前述的另一个基团,它以亲电子试剂形式引进的)的式III化合物。
一种制备式III化合物的方法,此时通式III中Z代表氮原子,该方法包括使通式XI的苯甲脒·氯化氢其中R2和m的定义同上,与式XII或它的盐反应,其中R1 1和R2 1各自的定义同上;合适的O-烷基是甲氧基或乙氧基,得到通式XIII的嘧啶酮,其中R1也可为羟基。
根据现有技术,如Tetrahedron,33,1675f(1979)和J.Org.Chem.,26,412f(1960)所述的方法可制得通式XI化合物。
式XI和XII的化合物反应可根据liebigs Ann.1980,1392f在有机溶剂中,合适的在醇类,优选的在乙醇中,在碱,合适的是金属烷醇盐,较好的是乙醇钠的存在下进行反应。
式XIII化合物接着可转化为式III化合物,它基本按据Davies和Pigott在J.Chem.Soc.,1945,347中所述的方法,通过使式XI-II化合物与磷酰卤或亚硫酰卤或碳酰氯,优选的是磷酰氯、磷酰溴,理想的是无溶剂,较高温度下反应得到式III化合物。
根据现有技术,如Tullock C.W.等在J.Am.Chem.Soc.1960,5197或Kiburis J.Klister J在J.Chem.Soc.Chem.Com.1969,381中所述的方法,可从R1是氯或氨基的式III化合物得到R1=F、其它定义同上的式III化合物。
可用已知方法制得式IV化合物。它们可制备并分离,或同容器中制备。一般来说,使通式XIV化合物:A-XH(XIV),其中A和X的定义同上)与合适的金属碱,例如碳酸金属盐或金属氢化物反应,优选的金属盐是钠盐或钾盐。
需要时,通式I化合物可分离,并用常规技术纯化。
本发明也提供了通式I化合物作为除草剂的用途。进一步的是,本发明又提供了用本发明的组合物或式I化合物处理施用地、在该处抑制不需要的植物生长的方法。因为对叶子喷洒施用是有效的,所以,最适合的施用地是作物区的植物,典型的作物是谷类、玉米、大豆、葵花或棉花。但是,因这些化合物有芽前除草作用,故也可施用于土壤,活性组份的剂量可在例如0.01-10kg/公顷,优选的在0.05-1kg/公顷的范围里。
本发明也涉及制备一种本发明的除草组合物的方法,该方法包括式I化合物和至少一种载体掺混。
优选的是本发明的组合物中至少有两种载体,其中之一是表面活性剂。
本发明组合物中的载体为与活性组份配好后能有助施用于植物种子或土壤,或适于储存、运输或处理的任何材料。载体可为固体或液体,包括一般为气相,但压缩后为液体形式的材料,以及在配制除草组合物中常规使用的任何载体。本发明优选的组合物含有0.5-95%(重量)活性组份。
合适的固体载体包括天然和合成的陶土和硅酸盐,例如,诸如硅藻土;如滑石粉的硅酸镁;如美国活性白土和蛭石的硅酸镁铝;如高岭土、蒙脱土和云母类的硅酸铝;碳酸钙;硫酸钙;硫酸铵的天然硅酸盐;合成的水合氧化硅和合成的硅酸钙或硅酸铝;例如碳和硫的元素;天然和合成树脂,如苯并呋喃树脂、聚氯乙烯和苯乙烯聚合物和共聚物;固体聚氯苯酚;沥青;蜡;如过磷酸钙的固体肥料。
合适的液体载体包括水;如异丙醇和多元醇类的醇;如丙酮、甲乙酮、甲基异丁基酮和环己酮的酮类;醚类;芳烃或芳烷烃,如苯、甲苯和二甲苯;石油馏份,如煤油和轻质矿物油;氯代烃,如四氯化碳、全氯乙烯和三氯乙烷。不同的液体混合物一般是合适的。
农用组合物一般配成浓缩形式储运,在施用前由使用者稀释。少量表面活性剂的载体存在有利于稀释工艺。因而在本发明的组合物中较好的有至少一种的载体是表面活性剂。例如,组合物可至少含两种载体,其中至少一种为表面活性剂。
表面活性剂可为乳化剂、分散剂或湿润剂;它可为非离子或离子表面活性剂,合适的表面活性剂的离子包括聚丙烯酸的钠盐或钙盐和木质素磺酸;在分子中含至少12个碳原子的脂肪酸或脂族胺或酰胺与环氧乙烷和/或环氧丙烷的缩合物;甘油醇、山梨醇、蔗糖或季戊四醇的脂肪酸酯及它们与环氧乙烷和/或环氧丙烷的缩合物;脂肪醇或烷基酚,如对-辛基酚或对-辛基甲酚与环氧乙烷和/或环氧丙烷的缩合物及这些缩合物的硫酸盐或磺酸盐;分子中含至少10个碳原子的硫酸酯或磺酸酯的碱金属或碱土金属盐,优选的是钠盐,例如,硫酸十二烷酯钠、硫酸仲烷酯钠、磺化蓖麻油的钠盐和诸如磺酸十二烷基苯酯的磺酸芳烷基酯钠;和环氧乙烷的聚合物和环氧乙烷和环氧丙烷的共聚物。
本发明的除草剂组合物也含有其它活性组份,如有杀虫或杀真菌性质的化合物或其它除草剂。
含本发明化合物的配方由100克活性组份(式I化合物)、30克分散剂、3克消泡剂、2克结构剂、50克防冻剂、0.5克杀生物剂和加到1000毫升的水所组成。使用前用水稀释到活性组分的所需浓度。
下列实施例阐述了本发明。下列实施例中制得的化合物结构用NMR和质谱予以确认。实施例实施例1β-二甲氨基乙基苯基(甲)酮·氯化氢
将苯乙酮(29.1ml,0.25摩尔)、仲甲醛(12.0g,0.40摩尔)和二甲胺·氯化氢(28.5g,0.35摩尔)悬浮于乙醇(50毫升)。加入浓盐酸(0.5毫升),将混合物加热回流4小时。然后加入丙酮(200毫升),让所得的澄清溶液冷却到室温。过滤收集沉淀,用乙醇结晶得无色晶体的标题化合物(40.7g,76.0%的理论得率),熔点为158℃。实施例2-4
如实施例1所例举的方法制得通式VI的另外化合物。细节如表1所示:
实施例 mp 得率
R2
号 (℃) (%)
2 3-三氟甲基 157 63
3 2,4-二氯 136 51
4 2,4-二甲基 134 72实施例56-苯基-2-吡啶酮
将2-氯乙酸乙酯(10.6ml,0.1摩尔)慢慢加入热的(105℃)吡啶(8.9毫升,0.11摩尔)中,将温度保持在100-110℃的范围里。所得的褐色油溶于乙醇(60毫升)中,加入β-二甲氨基乙基苯基酮·氯化氢(17.7克,0.1摩尔,按实施例1制得)和乙酸铵(60克),让混合物回流沸腾4小时。冷却后,过滤混合物,真空蒸去溶剂。残留物用水结晶,过滤收集,用甲苯重结晶。得到无色晶体的标题化合物(4.7克,28%理论得率),熔点为200℃。实施例6-8
这些实施例类似于实施例5的制法。细节列于表II。
实施例 mp 得率
R2
号 (℃) (%)
6 3-三氟甲基 174 36
7 2,4-二氯 255 56
8 2,4-二甲基 209 23实施例92-溴-6-苯基吡啶
将6-苯基吡啶酮(3克,17.5毫摩尔;根据实施例6制得)和磷酰溴(7.2g,25.0毫摩尔)的混合物在100℃下加热5小时。将冷却的混合物倒入水中(40毫升),通过加入碳酸钠饱和溶液将pH调到9。然后分离各层,水层用乙酸乙酯(50毫升)萃取。合并的有机层用无水硫酸镁干燥,真空蒸去溶剂。粗产物用乙醇水溶液结晶。接着用闪蒸柱色谱分离(硅胶,己烷/乙酸乙酯9/1v/v)纯化,得到淡褐色晶体的2-溴-6-苯基吡啶(3.1g,76%理论得率),熔点为50℃。实施例10-12
根据类似于实施例9的方法制得通式III的另外的化合物。细节列于表III。
表III
实施例 mp 得率
R2
号 (℃) (%)
10 3-三氟甲基 油 82
11 2,4-二氯 123 88
12 2,4-二甲基 油状 66实施例132-(1′-甲基-3′-三氟甲基吡唑-5′-基氧基)-6-苯基吡啶
让2-溴-6-苯基吡啶(0.5g,2.1毫摩尔;根据实施例9制得)、1-甲基-3-氟甲基-5-羟基吡唑(0.65g,3.9毫摩尔)、碳酸钾(0.6g,4.3毫摩尔)和N,N-二甲基甲酰胺(2毫升)的混合物回流加热12小时。然后将反应混合物直接进行闪蒸柱(硅胶)色谱分离。用己烷/乙酸乙酯(9/1v/v)洗脱得到淡黄色油的标题化合物(0.35g,52.0%理论得率)。实施例14-16
用实施例13的类似方法制得表IV的特定化合物。
实施例 mp 得率
A R2
号 (℃) (%)
14 1′-CH3-3′-CF3-吡唑-5′-基 3″-CF3 113 93
15 1′-CH3-3′-CF3-吡唑-5′-基 2″,4″-二氯 91 78
16 1′-CH3-3′-CF3-吡唑-5′-基 2″,4″-二甲基 油状95实施例172-氟-6-(4′-氟苯基)-吡啶
在-20℃下将丁基锂(105.0ml,0.26摩尔,2.5M的己烷溶液)加到1-溴-4-氟代苯(34.3ml,0.31摩尔)在无水乙醚(200毫升)的溶液中。将混合物搅拌60分钟,然后冷冻到-40℃。加入2,6-二氟吡啶(22.7ml,0.25摩尔),让反应混合物温热到室温。接着,用饱和的氯化铵水溶液(300毫升)洗涤混合物。分离各层,水层用乙醚洗涤3次(每次100毫升)。用无水硫酸镁干燥合并的有机层后,真空除去溶剂。粗制产物用闪蒸色谱柱分离(硅胶,己烷/乙酸乙酯8/2)纯化得到2-氟-6-(4′-氟苯基)-吡啶(19.8g,41.0%理论得率)的无色晶体,熔点为34℃。实施例182-氟-6-(4′-氟苯基)-4-甲基吡啶
在氮气下使2-溴-6-氟-4甲基吡啶(9.5g,50毫摩尔)、4-氟苯硼酸(7.8g,56毫摩尔)、碳酸钠(12.6g,150毫摩尔)、水和催化量的四(三苯基膦)钯(O)在二甲醚中的混合物加热回流过夜。反应混合物过滤后,减压除去溶剂。残留物在水和乙酸乙酯间分层。分离各层,水层用乙酸乙酯洗涤。用无水硫酸镁干燥合并的有机层后,真空除去溶剂。粗制物用闪蒸柱色谱分离(硅胶戊烷/乙酸乙酯9/11)纯化;得到2-氟-6.(4′-氟苯基)-4-甲基吡啶的无色晶体(3.7克,36.1%的理论得率),熔点为49℃。实施例19
在-70℃下向2-氟-6-(4-三氟苯基)吡啶(2.4克,10毫摩尔,按实施例1制得)的无水四氢呋喃(35毫升)溶液滴加2摩尔的LDA的四氢呋喃(7.5毫升,15毫摩尔)溶液。在-70℃下2小时后加二甲硫(1.41克,15毫摩尔)并让反应混合物保持-20℃。使混合物水解并用乙醚萃取。分离后用无水硫酸镁干燥有机层。除去溶剂并用闪蒸柱(硅胶)色谱分离纯化粗产物。用己烷/乙酸乙酯20/1v/v)洗脱得到标题化合物(1.2克,42%的理论得率),熔点为70-73℃。实施例20-23
用类似于实施例17的方法,制得表V的通式III化合物。
表V
实施例 mp 得率
R1 R2
号 (℃) (%)
20 - 油状 47
21 - 4′-三氟甲基 58 75
22 - 3′-三氟甲基 油状 72
23 3,4-二氟 油状 24实施例242-(3′-氯吡啶-5-基氧基-6-(4″-氟苯氧基)-吡啶使2-氟-6-(4″-氟苯基)-吡啶(1.9g,10.0毫摩尔,根据实施例17制得)、3-氯-5-羟基吡啶(1.4g,11.0毫摩尔)和碳酸钾(1.5g,11.0毫摩尔)在环丁砜(10毫升)中的混合物回流加热8小时。让混合物冷却到室温,然后通过硅胶床过滤,接着用乙酸乙酯洗涤、合并有机溶液,真空蒸去溶剂。将残留物加到闪蒸色谱柱(硅胶)的顶部,用己烷/乙酸乙酯(8/2v/v)洗脱得到淡褐色晶体的2-(3′-氯吡啶-5′-基氧基)-6-(4″-氟苯氧基)-吡啶(1.4g,46%理论得率),熔点为139℃。实施例25-39
类似于实施例24的方法制得另外的化合物,细节如表VI所示。
表VI实施例 mp 得率
R1 A R2号 (℃) (%)25 - 3′-CF3-苯基 4″-氟 油 4826 - 2′-氯吡啶-4′-基 4″-氟 137 3727 - 2′-氯吡啶-4′-基 - 109 3528 - 2′-氢吡啶-4′-基 4″-三氟甲基 105 5129 - 1′-CH3-3′-CF3-吡唑-5′-基 4″-氟 87 4430 - 1′-CH3-3′-CF3-吡唑-5′-基 4″-三氟甲基 94 5931 - 1′-CH3-3′-CF3-吡唑-5′-基 3″-三氟甲基 112 4432 - 2′-氯吡啶-4′-基 3″-三氟甲基 92 5433 - 2′,4″-二氟苯基 3″-三氟甲基 油 7234 3′-CF3-苯基 4″-三氟甲基 油 4435 4-CH3 1′-CH3-3′-CF3-吡唑-5′-基 4″-氟 85 4336 4-CH3 2′-氯吡啶-4′-基 4″-氟 115 3537 3-CH3S 3′-CF3-苯基 4″-三氟甲基 133-136 6738 3-CH3S 1′-CH3-3′-CF3-吡唑-5′-基 4″-三氟甲基 154-156 4139 1′-CH3-3′-CF3-吡唑-5′-基 3″,4″-二氟 油状 29实施例404-氟苄脒·氯化氢
将4-氟苄腈(10克,83毫摩尔)溶于无水乙醇(5毫升)和乙醚(70毫升)的混合物中。让反应混合物冷却到冰浴温度,用气体氯化氢饱和90分钟。让混合物温热到室温,并搅拌过夜。
滤出无色沉淀,用乙醚洗涤,并溶于无水乙醇(20毫升)中。加入用氨气饱和的乙醚(100毫升),让溶液搅拌3小时。
过滤所得的悬浮液,真空除去滤液的溶剂。残留物用二丙醚洗涤。干燥后得到熔点为210℃的无色晶体(5.15g,35.5%)。实施例41-50
用实施例40的类似方法进一步制得通式XI的化合物。细节列于表VII。
表VII
实施例 mp 得率
R2
号 (℃) (%)
41 4-三氟甲基 167 21.4
42 3-甲基 243 29.7
43 3-氯 148 17.5
44 3,4-二氟 185 17.4
45 3-三氟甲基 181 17.6
46 3-氟 143 20.0
47 4-溴 245 39
48 4-氯 >250 85
49 4-tbu 153 92
50 4-三氟甲氧基 210 57实施例512-(4′-氟苯基)-5-甲基-4-嘧啶酮
将氢化钠(0.52g,13毫摩尔)加到20毫升无水乙醇中,并在室温下搅拌30分钟。向内加入4-氟苯甲脒·氯化氢(1.47g,8.5毫摩尔)(来自实施例40),让混合物再搅拌30分钟。滴加入2-甲酰基丙酸甲酯(1克,10.6毫摩尔),在室温搅拌下使反应混合物放置4天。
冷却后,真空除去溶剂,将残留物溶于氢氧化钠水溶液(10毫升,1M)。然后用2摩尔盐酸将混合物的pH调到5。滤出沉淀,用二异丙醚洗涤。干燥后,得到熔点>250℃的无色晶体(0.44g,10.3%)。实施例526-羟基-2-(4′-三氟甲基苯基)-4-嘧啶酮
将4-三氟甲基苯甲脒·氯化氢(22.4g,0.1摩尔,来自实施例41)加到甲醇钾(0.22摩尔)在无水甲醇(65毫升)中的溶液内,在室温下搅拌15分钟。加入丙二酸二甲酯(12.6ml,0.11摩尔),让混合物加热回流4小时。冷却后,用甲醇(50毫升)稀释所得的悬浮液。
真空除去溶剂,将残留物溶于水(50毫升)。然后用浓盐酸将混合物的pH调到1、滤出沉淀,用水洗涤。干燥后得到熔点>200℃的淡黄色晶体(15.1g,59%)。实施例535-甲氧基-2-(4′氟甲基苯基)-4-嘧啶酮
在30分钟内向氢化钠(60%,6克,0.15摩尔)在无水THF(225毫升)中的悬浮液中加入甲氧基乙酸甲酯(14.9ml,0.15摩尔)在甲酸甲酯(11.1ml,0.18摩尔)中的溶液。在室温下将混合物搅拌2小时。加入乙醚(300毫升)后,用抽吸法可分离出甲氧基丙二酸甲酯单乙醛的钠盐。将钠盐(0.075摩尔)加到4-三氟甲基苯甲脒·氯化氢(16.8g,0.075摩尔,来自实施例41)在无水乙醇(150毫升)中,将混合物在室温下搅拌48小时。加热回流1小时后向混合物中加入水(100毫升),过滤溶液。
用乙酸将滤液的pH调到5,真空除去乙醇。滤出沉淀,用乙醇洗涤。干燥后得到熔点>200℃晶体(13.7g,68%)。实施例54-78
用实施例51的方法,制得通式III的进一步化合物。细节如表VIII所示。
表VIII实施例 mp 得率
R2号 (℃) (%)54 6-甲基 4′-氟 267 56.855 5-甲基 4′-三氟甲基 >250 58.756 6-甲基 4′-三氟甲基 209 82.257 5-甲基 3′-甲基 169 34.358 6-甲基 3′-甲基 185 41.659 5-甲基 3′-氯 260 61.460 6-甲基 3′-氯 218 5161 5-甲基 3′,4′-二氟 >250 59.462 6-甲基 3′,4′-二氟 225 51.363 5-甲基 3′三氟甲基 204 39.864 6-甲基 3′三氟甲基 109 26.665 5,6-二甲基 3′-三氟甲基 215 70.566 5,6-二甲基 4′-三氟甲基 242 63.567 5-甲基 4′-氯 >250 27.268 6-甲基 4′-氯 227 6.869 5-甲基 3′-氟 238 5670 6-甲基 3′-氟 194 48.471 6-乙基 4′-三氟甲基 181 8772 5-甲基 4′-溴 >250 2073 6-甲基 4′-溴 245 3974 6-甲基 4′-叔丁基 218 8175 6-甲基 4′-叔丁基 213 7576 5,6-二甲基 4′-氯 276 4477 5,6-二甲基 4′-三氟甲氧基 228 7078 6-甲基 4′-三氟甲氧基 196 95实施例792-(4′-氟苯基)-4-氯-5甲基嘧啶
使2-(4′-氟苯基)-5-甲基-4-嘧啶酮(0.79g,3.9毫摩尔)(来自实施例51)和磷酰氯(3毫升)回流加热1小时。
真空除去过量的磷酰氯,用水(10毫升)骤冷残留物并水解残留试剂。中和混合物,然后用乙酸乙酯(50毫升)萃取。有机层用无水硫酸镁干燥后,真空除去溶剂。得到熔点为133℃的无色晶体的标题化合物(0.63克,72.6%)。实施例802-(4′-氯苯基)-4,5-二氯-6-甲氧基嘧啶
向2-(4′-氯苯基)-4,5,6-三氯嘧啶(1.85g,6.3毫摩尔)在甲醇(25毫升)和THF(60毫升)中的溶液中加入钠(0.145g,6.3毫摩尔)在甲醇(10毫升)中的溶液,让混合物在室温下搅拌过夜。真空除去溶剂后向残留物中加入二氯甲烷,所得的混合物用水洗涤。有机层用无水硫酸镁干燥后除去溶剂。用戊烷处理残留物得到无色晶体的标题化合物(1.75g,96%),熔点为157-159℃。实施例81-108
用类似于实施例79的方法制得表IX列出的通式(XIII)化合物。
R1 R2号 (℃) (%)81 6-甲基 4′-氟 143 9782 6-甲基 4′-三氟甲基 62 71.883 5-甲基 4′-三氟甲基 109 87.384 5-甲基 3′-甲基 154 98.885 6-甲基 3′-甲基 134 73.786 5-甲基 3′-氯 87 94.187 6-甲基 3′-氯 101 26.188 5-甲基 3′,4′-二氟 114 9289 6-甲基 3′,4′-二氟 94 90.790 5,6-二甲基 3′-三氟甲基 83 81.691 5,6-二甲基 4′-三氟甲基 57 54.592 5-甲基 3′-三氟甲基 101 81.493 6-甲基 3′-三氟甲基 62 87.394 5-甲基 4′-氯 162 85.295 6-甲基 4′-氯 101 83.696 5-甲基 3′-氟 95 83.797 6-甲基 3′-氟 86 71.598 6-乙基 4′-三氟甲基 35 8699 5-甲基 4′-溴 156-158 94100 6-甲基 4′-溴 101-112 94101 5-甲基 4′-tbu 103-105 98102 6-甲基 4′-tbu 70-71 99103 5,6-二甲基 4′-氯 87 71104 5,6-二甲基 4′-三氟甲氧基 76 81105 5-甲基 4′-三氟甲氧基 129 91106 6-甲基 4′-三氟甲氧基 64 94107 6-氯 4′-三氟甲基 80 33108 5-甲氧基 4′-三氟甲基 108 31实施例1092-(4′-氟苯基)-4-(3″-三氟甲基苯氧基)-6-甲基嘧啶
使2-(4′-氟苯基)-4-氯-甲基吡啶(0.6g,2.7毫摩尔)(来自实施例81)、α,α,α-3-羟基三氟甲苯(0.49g,3毫摩尔)和碳酸钾(0.41克,3毫摩尔)在N,N-二甲基甲酰胺(3毫升)中的混合物加热回流2小时。
冷却后,加入乙酸乙酯(10毫升),悬浮液用乙酸乙酯经硅胶床过滤。真空除去滤液的溶剂,残留物用闪蒸硅胶柱色谱分离纯化,用己烷/乙酸乙酯7/2洗脱。除去溶剂得到熔点为58℃的无色晶体(0.53g,56.4%)。实施例110-183
根据实施例109的方法制得通式I的进一步化合物。细节列于表X。
表X实施例 mp 得率
R1 R2 A号 (℃) (%)110 5-甲基 4′-氟 1″-CH3-3″-CF3-吡唑-5″-基 133 54.7111 6-甲基 4′-氟 1″-CH3-3″-CF3-吡唑-5″-基 123 21112 6-甲基 4′-CF3 1″-CH3-3″-CF3-吡唑-5″-基 98 39.5113 6-甲基 4′-CF3 3″-CF3-苯基 89 79.9114 5-甲基 4′-CF3 1″-CH3-3″-CF3-吡唑-5″-基 147 27.6115 5-甲基 4′-CF3 3″-CF3-苯基 95 97.6116 5-甲基 3′-CF3 1″-CH3-3″-CF3-吡唑-5″-基 121 74.9117 5-甲基 3′-CF3 3″-CF3-苯基 71 74.5118 6-甲基 3′-CF3 1″-CH3-3″-CF3-吡唑-5″-基 113 74.9119 6-甲基 3′-CF3 3″-CF3-苯基 60 73.2120 5-甲基 3′-氯 1″-CH3-3″-CF3-吡唑-5″-基 116 35.4121 5-甲基 3′-氯 3″-CF3-苯基 105 52.4122 6-甲基 3′-氯 1″-CH3-3″-CF3-吡唑-5″-基 96 27.1123 5-甲基 2′,4′-二氟 3″-CF3-苯基 68 40.4124 5-甲基 2′,4′-二氟 2″-氯吡啶-4″-基 146 58.8125 6-甲基 2′,4′-二氟 1″-CH3-3″-CF3-吡唑-5″-基 78 56.4126 6-甲基 2′,4′-二氟 3″-CF3-苯基 64 65.3127 6-甲基 2′,4′-二氟 2″-氯吡啶-4″-基 162 31.7128 5-甲基 4′-CF3 2″-氯吡啶-4″-基 99 44.1129 5,6-二甲基 4′-CF3 1″-CH3-3″-CF3-吡唑-5″-基 136 13.2130 5,6-二甲基 4′-CF3 3″-CF3-苯基 73 65.6131 5,6-二甲基 3′-CF3 1″-CH3-3″-CF3-吡唑-5″-基 132 30.3132 5,6-二甲基 3′-CF3 3″-CF3-苯基 105 67.5133 6-甲基 4′-CF3 1″-CH3-3″-CF3-吡唑-5″-基 128 41134 6-甲基 4′-CF3 2″,2″-二氟-1″,3″-苯并间二氧杂戊烯基-4″-基 86 85135 6-乙基 4′-CF3 1″-CH3-3″-CF3-吡唑-5″-基 75 46136 6-乙基 4′-CF3 2″-氯吡啶-4″-基 97 41137 6-甲基 3′-CF3 4″-氟苯基 78 92138 6-乙基 4′-CF3 3″-CF3-苯基 65 38139 5-甲基 3′-CF3 4″-氟苯基 109-111 86140 5-甲基 4′-Br 3″-CF3-苯基 110 100141 6-甲基 4′-Br 3″-CF3-苯基 86-88 89142 5-甲基 4′-tBu 1″-CH3-3″-CF3-吡唑-5″-基 149-151 92143 6-甲基 4′-tBu 1″-CH3-3″-CF3-吡唑-5″-基 119-121 78144 5-甲基 4′-tBu 3″-CF3-苯基 123-124 91145 6-甲基 4′-tBu 3″-CF3-苯基 油状 99146 6-甲基 4′-Cl 3″-CF3-苯基 68 29147 5,6-二甲基 4′-Cl 1″-CH3-3″-CF3-吡唑-5″-基 142 49148 5,6-二甲基 4′-Cl 2″-氯吡啶-4″-基 150 36149 5,6-二甲基 4′-Cl 3″-CF3-苯基 102 66150 5-甲基 1″-CH3-3″-CF3-吡唑-5″-基 140-150 75151 5,6-二甲基 3′-F 1″-CH3-3″-CF3-吡唑-5″-基 117 70152 5-甲基 4′-Cl 1″-CH3-3″-CF3-吡唑-5″-基 141 58153 5-甲基 4′-Cl 2″-氯吡啶-4″-基 125 31154 5-甲基 4′-Cl 3″-CF3-苯基 101 52155 6-甲基 2″-氯吡啶-4″-基 1″-CH3-3″-CF3-吡唑-5″-基 99 37156 6-甲基 4′-Cl 2″-氯吡啶-4″-基 151 8157 5-甲基 3′,4′-二氟 2″-氯吡啶-4″-基 146 59158 6-甲基 3′,4′-二氟 1″-CH3-3″-CF3-吡唑-5″-基 78 56159 6-甲基 3′,4′-二氟 3″-CF3-苯基 64 65160 6-甲基 3′,4′-二氟 2″-氯吡啶-4″-基 162 32161 5-甲基 4′-CF3O 1″-CH3-3″-CF3-吡唑-5″-基 117-121 58162 6-甲基 4′-CF3O 1″-CH3-3″-CF3-吡唑-5″-基 102-104 46163 5-甲基 4′-CF3O 1″-CH3-3″-CF3-吡唑-5″-基 96-98 58164 6-甲基 4′-CF3O 1″-CH3-3″-CF3-吡唑-5″-基 88-89 78165 6-甲基 4′-CF3 1″-CH3-3″-CF3-吡唑-5″-基 87-90 83166 6-甲基 4′-CF3O 3″-CF3-苯基 52 73167 6-甲基 4′-CF3O 2″-氯吡啶-4″-基 72 32168 5-甲基 4′-CF3O 3″-CF3-苯基 83 80169 5-甲基 4′-CF3O 2″-氯吡啶-4″-基 82 43170 5,6-二甲基 4′-CF3O 3″-CF3-苯基 75 66171 5,6-二甲基 4′-CF3O 2″-氯吡啶-4″-基 107 54172 5-甲基 3′,4′-二氟 3″-CF3-苯基 68 40173 6-甲基 4′-CF3O 1″-CH3-3″-CF3-吡唑-5″-基 116 43174 5-甲基 4′-CF3O 1″-CH3-3″-CF3-吡唑-5″-基 98 67175 5,6-二甲基 4′-CF3O 1″-CH3-3″-CF3-吡唑-5″-基 128 45176 6-甲氧基甲基 4′-Cl 2″-氯吡啶-4″-基 9-91 100177 6-甲氧基甲基 4′-Cl 1″-CH3-3″-CF3-吡唑-5″-基 113-115 94178 6-甲氧基甲基 4′-Cl 3″-CF3-苯基 140-142 92179 5-甲氧基 4′-CF3 2″-氯吡啶-4″-基 96 92180 5-甲氧基 4′-CF3 3″-CF3-苯基 80 95181 5-氯-6-甲氧基 4′-Cl 1″-CH3-3″-CF3-吡唑-5″-基 173-176 95182 5-氯-6-甲氧基 4′-Cl 3″-CF3-苯基 95-98 100183 5-甲氧基 4′-CF3 1″-CH3-3″-CF3-吡唑-5″-基 80 180实施例1844,6-二(2″-氯吡啶-4′-基氧基)-2-(4′-三氟甲基苯基)嘧啶
使4,6-二氯-2-(4′-三氟甲基苯基)嘧啶(2.93g,10毫摩尔)(来自实施例107)、2-氯-4-羟基吡啶(2.85g,22毫摩尔)和碳酸钾(3.04g,22毫摩尔)在无水N,N-二甲基甲酰胺(20毫升)中的混合物在80℃下加热1小时。
冷却后,真空除去溶剂,加入乙酸乙酯/己烷1/1(10毫升),经硅胶床过滤悬浮液。所得的溶液用水洗涤3次。有机层用硫酸镁干燥后除去溶剂,残留物经闪蒸硅胶柱色谱分离纯化,用己烷/乙酸乙酯8/2洗脱。除去溶剂得到熔点为141℃的无色晶体。实施例185-187
用类似于实施例184的方法制得列于表XI的通式(XVa)化合物。
表XI实施例 mp 得率
R2号 (℃) (%)185 4′-三氟甲基 1″-CH3-3″-CF3-吡唑-5″-基168 86186 4′-三氟甲基 3″-CF3-苯基 92 88187 4′-氯 1″-CH3-3″-CF3-吡唑-5″-基156 93实施例1886-甲氧基-4-(1″-甲基-3″-三氟甲基吡唑-5″-基)-2-(4′-三氟甲基苯基)嘧啶
将4,6-二(2″-氯吡啶-4″-基氧基)-2-(4′-三氟甲基苯基)嘧啶(2.0g,4.2毫摩尔)(来自实施例184)溶于无水甲醇(5毫升),向该溶液中滴加甲醇钾(4.2毫摩尔)在甲醇(1.2毫升)中的溶液,使混合物加热回流30分钟。
真空除去溶剂,残留物用闪蒸硅胶柱色谱分离纯化,用己烷/乙酸乙酯9/1洗脱。除去溶剂得到熔点为128℃的无色晶体(1.0克,62%)。实施例1894,6-二溴-2-(4′-三氟甲基苯基)嘧啶
使4,6-二羟基-2-(4′-三氟甲基苯基)嘧啶(5.12克,20毫摩尔)和磷酰溴(10毫升)在100℃下加热3小时。将所得的热悬浮液加到冰中,用吸液法分离产物。干燥后得到熔点为87℃的将近无色的晶体(6.5克,86%)。实施例190-201
用实施例188或109的方法制得通式I的化合物,细节如表XII所示。
R1 R2 A号 (℃) (%)190 6-甲氧基 4′-CF3 1″-CH3-3″-CF3-吡唑-5″-基130 64191 6-甲氧基 4′-CF3 3″-CF3-苯基 94 94192 6-甲硫基 4′-CF3 1″-CH3-3″-CF3-吡唑-5″-基127 55193 6-甲硫基 4′-CF3 2″-氯吡啶-4″-基 106 41194 6-二甲氨基 4′-CF3 1″-CH3-3″-CF3-吡唑-5″-基148 90195 6-乙氨基 4′-CF3 1″-CH3-3″-CF3-吡唑-5″-基102 23196 6-甲氧基 4′-Cl 1″-CH3-3″-CF3-吡唑-5″-基144 80197 6-甲氧基氨基 4′-Cl 1″-CH3-3″-CF3-吡唑-5″-基178 16198 6-二甲氨基 4′-Cl 1″-CH3-3″-CF3-吡唑-5″-基143 13199 6-氨基 4′-Cl 1″-CH3-3″-CF3-吡唑-5″-基149 80200 6-甲氨基 4′-Cl 1″-CH3-3″-CF3-吡唑-5″-基114 97201 6-溴 4′-CF3 1″-CH3-3″-CF3-吡唑-5″-基110 57202 6-氯 4′-Cl 1″-CH3-3″-CF3-吡唑-5″-基122 26203 6-氯 4′-CF3 1″-CH3-3″-CF3-吡唑-5″-基113 69实施例2046-乙烯基-4-(1″-甲基-3″-三氟甲基吡唑-5″-基)-2-(4′-三氟甲基苯基)嘧啶
使6-溴-4-(1″-甲基-3″-三氟甲基吡唑-5″-基)-2-(4′-三氟甲基苯基)嘧啶(2克,4.3毫摩尔,来自实施例201)、锡酸乙烯基三丁基酯(1.4ml,4.7毫摩尔)、四(三苯基膦)钯(O)(0.1g,0.09毫摩尔)、甲苯(20毫升)和3晶体的2,6-二叔丁基-4-甲酚的混合物回流加热90分钟。冷却后,加入1.2N氟化吡啶鎓在THF/吡啶(4毫升)中的溶液和2毫升吡啶。在室温下搅拌溶液17小时。向所得的混合物中加入乙酸乙酯(100毫升),溶液用水和饱和的碳酸氢纳溶液洗涤两次。有机层用无水硫酸镁干燥后,除去溶剂,残留物用闪蒸硅胶柱色谱分离纯化,用己烷/乙酸乙酯7/3洗脱。除去溶剂得到熔点为112℃的将近无色的晶体(1.45克,82%)。实施例205除草活性
为了评价它们的除草活性,用代表范围的植物试验本发明的化合物:TRZAS 小麦HORVW 大麦GOSHI 陆地棉HELAN 向日葵ORYSA 稻GLXMA 大豆BEAVA 甜菜ZEAMX 玉米ALMY 看麦娘AVEFA 野燕麦ECHCG 稗SETVI 狗尾草GALAP 猪秧秧STEME 繁缕CHEAL 白藜VERPE 灯笼婆婆纳LAMPU 紫花野芝麻VIOAR 堇菜SIDSP 有刺黄花稔AMBAR 豚草ABUTH 苘麻IPOPU 圆叶牵牛SINAL 欧白芥AMARE 反枝苋
该试验有两个范畴。芽前和芽后试验。芽前试验涉及将化合物的液体配方物喷洒在最近播种过上述种类的植物种子的土壤里。芽后试验涉及用这类配方液体喷洒在上述种类的秧苗上。
用于试验的土壤是制备的园林肥土。试验中用的配方从试验化合物在含0.4%(重量)烷基苯基/环氧乙烷缩合物的表面活性剂(商品名为TRITON X155)的丙酮溶液中制得。丙酮溶液用水稀释,所得的配方物的剂量水平相当于1000克或300克活性物质/公顷,体积当量为400升/公顷。在芽前试验中的未处理播种土壤和芽后试验中带有未处理秧苗植物的未处理土壤作为对照。
试验化合物的除草效果在喷洒叶子和土壤后20天肉眼观察评价,(对于实施例13-16是处理后13天观察),以0-9级记录。0级表示未处理对照物的生长,9级表示死亡。在线性等级上增加1个单位约表示增加10%的效果。*表示特定的植物种类在试验中未作处理。
试验结果列于下表,其中的化合物与前述实施例相同。*表示特定的植物种类在试验中未处理。
实施例序号 | 剂量 | 施用时间 | TRZAW | HORVW | GOSHI | HELAN | ORYSA | GLXMA | BEAVA | ZEAMX | ALOMY | AVEFA | ECHCG | SETVI | GALAP | STEME | CHEAL | VERPE | LAMPU | VIOAR | SIDSP | AMBAR | ABUTH | IPOPU | SINAL | AMARE |
13 | 1000 | 前后 | ** | ** | ** | ** | 02 | 05 | 48 | 24 | ** | 22 | 45 | ** | ** | ** | ** | ** | ** | ** | ** | ** | ** | ** | 58 | ** |
14 | 1000 | 前后 | ** | ** | ** | ** | 34 | 46 | 99 | 96 | ** | 66 | 87 | ** | ** | ** | ** | ** | ** | ** | ** | ** | ** | ** | 88 | ** |
15 | 1000 | 前后 | ** | ** | ** | ** | 02 | 26 | 89 | 25 | ** | 22 | 57 | ** | ** | ** | ** | ** | ** | ** | ** | ** | ** | ** | 66 | ** |
16 | 1000 | 前后 | ** | ** | ** | ** | 00 | 02 | 27 | 04 | ** | 02 | 22 | ** | ** | ** | ** | ** | ** | ** | ** | ** | ** | ** | 25 | ** |
24 | 300 | 前后 | 10 | 00 | 01 | 01 | ** | ** | ** | 01 | 00 | ** | ** | 00 | 00 | 00 | ** | 00 | ** | 00 | ** | ** | ** | 00 | ** | ** |
25 | 300 | 前后 | 00 | 00 | 01 | 02 | ** | ** | ** | 02 | 00 | ** | ** | 10 | 00 | 00 | ** | 01 | ** | 01 | ** | ** | ** | 01 | ** | ** |
26 | 300 | 前后 | 11 | 02 | ** | 13 | ** | ** | ** | 12 | ** | ** | ** | 00 | 22 | 04 | 00 | 04 | ** | ** | ** | ** | 04 | 01 | ** | 05 |
27 | 300 | 前后 | 02 | 02 | ** | 03 | ** | ** | ** | 03 | ** | ** | ** | 01 | 01 | 02 | 00 | 03 | ** | ** | ** | ** | 03 | 02 | ** | 04 |
28 | 300 | 前后 | 03 | 33 | 04 | 05 | ** | ** | ** | 34 | 55 | ** | 64 | 96 | 25 | 74 | ** | 96 | 8* | 86 | 46 | 45 | 44 | 24 | ** | 96 |
29 | 300 | 前后 | 04 | 13 | ** | 04 | ** | ** | ** | 03 | ** | ** | ** | 83 | 03 | 75 | 86 | 88 | ** | ** | ** | ** | 05 | 04 | ** | 97 |
30 | 300 | 前后 | 44 | 65 | 36 | 36 | ** | ** | ** | 44 | 96 | ** | 86 | 97 | 65 | 96 | ** | 96 | 9* | 87 | 88 | 85 | 66 | 66 | ** | 95 |
31 | 300 | 前后 | 13 | 45 | 28 | 05 | ** | 35 | ** | 18 | 87 | ** | 54 | 97 | 76 | 97 | ** | 99 | 97 | 88 | ** | ** | 88 | 56 | ** | 97 |
32 | 300 | 前后 | 12 | 02 | 05 | 04 | ** | 03 | ** | 03 | 33 | ** | 22 | 84 | 14 | 65 | ** | 89 | 35 | 87 | ** | ** | 34 | 15 | ** | 95 |
实施例序号 | 剂量 | 施用时间 | TRZAW | HORVW | GOSHI | HELAN | ORYSA | GLXMA | BEAVA | ZEAMX | ALOMY | AVEFA | ECHCG | SETVI | GALAP | STEME | CHEAL | VERPE | LAMPU | VIOAR | SIDSP | AMBAR | ABUTH | IPOPU | SINAL | AMARE |
33 | 300 | 前后 | 20 | 00 | 00 | 00 | ** | 20 | ** | 00 | 00 | ** | 00 | 02 | 00 | 00 | ** | 00 | 00 | 00 | ** | ** | 00 | 51 | ** | 00 |
34 | 300 | 前后 | 12 | 32 | 35 | ** | 32 | 17 | ** | 22 | 74 | ** | 84 | 85 | 26 | 86 | ** | 99 | 86 | 96 | ** | 85 | 36 | 56 | ** | 87 |
39 | 300 | 前后 | 11 | 32 | 04 | ** | ** | 03 | ** | 03 | 53 | ** | 42 | 97 | 25 | 95 | ** | 99 | 85 | 97 | ** | 33 | 33 | 35 | ** | 95 |
109 | 300 | 前后 | 00 | 00 | 02 | 00 | ** | ** | ** | 00 | 00 | ** | 00 | 01 | 00 | 00 | 60 | 07 | 00 | 00 | 01 | ** | 00 | 02 | ** | 61 |
110 | 300 | 前后 | 34 | 45 | 26 | 16 | ** | ** | ** | 24 | 87 | ** | 67 | 96 | 28 | 97 | ** | 99 | 97 | 98 | 96 | ** | 56 | 34 | ** | 96 |
111 | 300 | 前后 | 13 | 33 | 05 | 05 | ** | ** | ** | 04 | 84 | ** | ** | 96 | 56 | 98 | 89 | 99 | 88 | ** | 66 | ** | 56 | 34 | ** | 96 |
112 | 300 | 前后 | 34 | 55 | 68 | 38 | ** | 58 | ** | 45 | 97 | ** | 86 | 98 | 87 | 98 | ** | 99 | 98 | 89 | ** | ** | 88 | 97 | ** | 98 |
113 | 300 | 前后 | 34 | 65 | 68 | 28 | ** | 38 | ** | 35 | 96 | ** | 87 | 99 | 87 | 98 | ** | 99 | 88 | 88 | ** | ** | 98 | 98 | ** | 97 |
114 | 300 | 前后 | 44 | 55 | 88 | 36 | ** | 46 | ** | 36 | 88 | ** | 85 | 98 | 87 | 98 | ** | 99 | 88 | 88 | ** | ** | 98 | 98 | ** | 97 |
115 | 300 | 前后 | 44 | 76 | 89 | 38 | ** | 58 | ** | 46 | 87 | ** | 86 | 98 | 87 | 98 | ** | 98 | 98 | 88 | ** | ** | 98 | 98 | ** | 98 |
116 | 300 | 前后 | 02 | 33 | 04 | 04 | ** | 05 | ** | 03 | 63 | ** | 42 | 98 | 03 | 64 | ** | 99 | 87 | 75 | ** | ** | 24 | 45 | ** | 85 |
117 | 300 | 前后 | 03 | 23 | 04 | 04 | ** | 04 | ** | 24 | 74 | ** | 53 | 94 | 14 | 54 | ** | 99 | 65 | 87 | ** | ** | 44 | 45 | ** | 97 |
118 | 300 | 前后 | 00 | 02 | 04 | 04 | ** | 03 | ** | 02 | 33 | ** | 43 | 74 | 13 | 23 | ** | 89 | 34 | 75 | ** | ** | 12 | 24 | ** | 95 |
119 | 300 | 前后 | 00 | 02 | 00 | 02 | ** | 01 | ** | 01 | 01 | ** | 10 | 01 | 02 | 02 | ** | 03 | 01 | 25 | ** | ** | 01 | 03 | ** | 04 |
实施例序号 | 剂量 | 施用时间 | TRZAW | HORVW | GOSHI | HELAN | ORYSA | GLXMA | BEAVA | ZEAMX | ALOMY | AVEFA | ECHCG | SETVI | GALAP | STEME | CHEAL | VERPE | LAMPU | VIOAR | SIDSP | AMBAR | ABUTH | IPOPU | SINAL | AMARE |
120 | 300 | 前后 | 12 | 34 | 25 | 04 | ** | 05 | ** | 23 | 85 | ** | 64 | 95 | 66 | 94 | ** | 89 | 88 | 87 | ** | ** | 55 | 54 | ** | 95 |
121 | 300 | 前后 | 23 | 34 | 28 | 04 | ** | 15 | ** | 35 | 85 | ** | 76 | 97 | 36 | 85 | ** | 99 | 77 | 88 | ** | ** | 54 | 45 | ** | 96 |
122 | 300 | 前后 | ** | ** | ** | ** | ** | ** | ** | ** | ** | ** | ** | ** | ** | ** | ** | ** | ** | ** | ** | ** | ** | ** | ** | ** |
123 | 300 | 前后 | 01 | 01 | 02 | 03 | ** | 02 | ** | 01 | 01 | ** | 02 | 02 | 03 | 04 | ** | 25 | 23 | 45 | ** | ** | 02 | 06 | ** | 44 |
124 | 300 | 前后 | 14 | 34 | 26 | 15 | ** | 55 | ** | 55 | 55 | ** | 66 | 87 | 34 | 95 | ** | 99 | 86 | 98 | ** | ** | 76 | 97 | ** | 96 |
125 | 300 | 前后 | 34 | 45 | 35 | 25 | ** | 36 | ** | 55 | 85 | ** | 76 | 97 | 45 | 96 | ** | 99 | 96 | 98 | ** | ** | 95 | 77 | ** | 96 |
126 | 300 | 前后 | 02 | 02 | 05 | 04 | ** | 03 | ** | 03 | 33 | ** | 03 | 93 | 14 | 74 | ** | 89 | 45 | 88 | ** | ** | 24 | 36 | ** | 95 |
127 | 300 | 前后 | 00 | 01 | 14 | 03 | ** | 02 | ** | 22 | 23 | ** | 02 | 84 | 03 | 75 | ** | 76 | 34 | 88 | ** | ** | 24 | 46 | ** | 86 |
128 | 300 | 前后 | 45 | 55 | 76 | 25 | ** | 35 | ** | 56 | 86 | ** | 77 | 97 | 56 | 96 | ** | 99 | 96 | 98 | ** | ** | 96 | 98 | ** | 97 |
129 | 300 | 前后 | 32 | 34 | 57 | 45 | ** | 35 | ** | 33 | 85 | ** | 65 | 96 | 55 | 95 | ** | 99 | 96 | 98 | ** | ** | 96 | 99 | ** | 96 |
130 | 300 | 前后 | 22 | 54 | 36 | 25 | ** | 35 | ** | 34 | 75 | ** | 65 | 97 | 45 | 96 | ** | 98 | 66 | 98 | ** | ** | 75 | 69 | ** | 86 |
131 | 300 | 前后 | 01 | 01 | 23 | 24 | ** | 02 | ** | 21 | 12 | ** | 02 | 82 | 04 | 44 | ** | 77 | 04 | 87 | ** | ** | 04 | 55 | ** | 84 |
132 | 300 | 前后 | 00 | 01 | 03 | 02 | ** | 32 | ** | 01 | 00 | ** | 01 | 32 | 03 | 03 | ** | 04 | 03 | 35 | ** | ** | 02 | 35 | ** | 55 |
133 | 400 | 前后 | 53 | 54 | ** | ** | 55 | 76 | ** | 44 | 88 | ** | ** | 98 | 79 | ** | ** | 98 | 98 | ** | ** | ** | 99 | 99 | ** | ** |
实施例序号 | 剂量 | 施用时间 | TRZAW | HORVW | GOSHI | HELAN | ORYSA | GLXMA | BEAVA | ZEAMX | ALOMY | AVEFA | ECHCG | SETVI | GALAP | STEME | CHEAL | VERPE | LAMPU | VIOAR | SIDSP | AMBAR | ABUTH | IPOPU | SINAL | AMARE |
134 | 400 | 前后 | 32 | 43 | ** | ** | 32 | 46 | ** | 43 | 84 | ** | ** | 98 | 37 | ** | ** | 99 | 78 | ** | ** | ** | 69 | 49 | ** | ** |
135 | 300 | 前后 | 64 | 76 | ** | ** | 54 | 46 | ** | 33 | 87 | ** | 86 | 97 | 36 | 87 | *8 | 99 | 89 | ** | ** | ** | 87 | 99 | ** | ** |
136 | 300 | 前后 | 65 | 86 | ** | ** | 55 | 46 | ** | 44 | 86 | ** | 87 | 87 | 16 | 98 | *6 | 99 | 87 | ** | ** | ** | 68 | 98 | ** | ** |
137 | 300 | 前后 | 00 | 01 | ** | ** | 01 | 01 | ** | 00 | 01 | ** | 00 | 00 | 01 | 01 | 5* | 02 | 02 | ** | ** | ** | 01 | 02 | ** | ** |
138 | 300 | 前后 | 64 | 77 | ** | ** | 44 | 47 | ** | 33 | 86 | ** | 86 | 97 | 45 | 97 | *7 | 99 | 98 | ** | ** | ** | 77 | 98 | ** | ** |
139 | 300 | 前后 | 01 | 02 | ** | ** | 01 | 02 | ** | 00 | 01 | ** | 01 | 01 | 01 | 01 | *4 | 03 | 02 | ** | ** | ** | 02 | 04 | ** | ** |
140 | 300 | 前后 | 43 | 54 | 55 | ** | 35 | 25 | ** | 23 | 87 | ** | 84 | 88 | 47 | 96 | ** | 99 | 98 | 96 | ** | 86 | 48 | 69 | ** | 89 |
141 | 300 | 前后 | 12 | 43 | 29 | ** | 22 | 14 | ** | 23 | 74 | ** | 83 | 95 | 15 | 95 | ** | 98 | 87 | 86 | ** | 56 | 25 | 49 | ** | 59 |
142 | 300 | 前后 | 00 | 01 | 15 | ** | 00 | 14 | ** | 02 | 00 | ** | 11 | 51 | 12 | 43 | ** | 55 | 14 | 76 | ** | 05 | 03 | 15 | ** | 05 |
143 | 300 | 前后 | 01 | 12 | 48 | ** | 20 | 23 | ** | 23 | 61 | ** | 52 | 83 | 36 | 95 | ** | 98 | 85 | 96 | ** | 87 | 46 | 57 | ** | 88 |
144 | 300 | 前后 | 01 | 01 | 06 | ** | 00 | 23 | ** | 02 | 00 | ** | 01 | 31 | 04 | ** | ** | 46 | 43 | 45 | ** | 05 | 03 | 44 | ** | 36 |
145 | 300 | 前后 | 01 | 02 | 28 | ** | 00 | 14 | ** | 13 | 21 | ** | 22 | 52 | 05 | 35 | ** | 67 | 35 | 66 | ** | 26 | 05 | 25 | ** | 58 |
146 | 300 | 前后 | 00 | 00 | 04 | 05 | ** | 11 | ** | 04 | 75 | ** | 34 | 89 | 04 | 86 | ** | 97 | 44 | 87 | ** | 44 | 33 | 14 | ** | 94 |
147 | 300 | 前后 | 00 | 10 | 04 | 05 | ** | 14 | ** | 01 | 54 | ** | 33 | 75 | 04 | 65 | ** | 96 | 34 | 75 | ** | 34 | 34 | 35 | ** | 94 |
实施例序号 | 剂量 | 施用时间 | TRZAW | HORVW | GOSHI | HELAN | ORYSA | GLXMA | BEAVA | ZEAMX | ALOMY | AVEFA | ECHCG | SETVI | GALAP | STEME | CHEAL | VERPE | LAMPU | VIOAR | SIDSP | AMBAR | ABUTH | IPODU | SINAL | AMARE |
148 | 300 | 前后 | 00 | 00 | 03 | 04 | ** | 02 | ** | 02 | 11 | ** | 01 | 23 | 04 | 03 | ** | 84 | 03 | 86 | ** | 03 | 12 | 04 | ** | 94 |
149 | 300 | 前后 | 00 | 00 | 30 | 04 | ** | 02 | ** | 02 | 00 | ** | 00 | 02 | 04 | 03 | ** | 25 | 14 | 54 | ** | 04 | 01 | 04 | ** | 84 |
150 | 300 | 前后 | 22 | 44 | 46 | 25 | ** | 34 | ** | 44 | 86 | ** | 76 | 98 | 25 | 95 | ** | 97 | 97 | 97 | ** | 76 | 46 | 66 | ** | 97 |
151 | 300 | 前后 | 00 | 01 | 04 | 25 | ** | 03 | ** | 03 | 42 | ** | 02 | 04 | 04 | 65 | ** | 86 | 24 | 97 | ** | 44 | 12 | 14 | ** | 96 |
152 | 300 | 前后 | 32 | 44 | 56 | 46 | ** | 35 | ** | 45 | 88 | ** | 76 | 79 | 47 | 97 | ** | 97 | 87 | 97 | ** | 87 | 76 | 95 | ** | 87 |
153 | 300 | 前后 | 14 | 34 | 35 | 06 | ** | 14 | ** | 34 | 86 | ** | 75 | 78 | 15 | 96 | ** | 98 | 85 | 96 | ** | 44 | 55 | 55 | ** | 95 |
154 | 300 | 前后 | 45 | 56 | 4* | 2* | ** | 25 | ** | 47 | 8* | ** | 8* | 9* | 3* | 9* | ** | 9* | 9* | 9* | ** | 8* | 7* | 7* | ** | 9* |
155 | 300 | 前后 | 31 | 45 | 46 | 16 | ** | 15 | ** | 36 | 86 | ** | 87 | 98 | 46 | 97 | ** | 97 | 85 | 97 | ** | 85 | 86 | 65 | ** | 95 |
156 | 300 | 前后 | 20 | 21 | 04 | 05 | ** | *4 | ** | 04 | 65 | ** | 44 | 99 | 05 | 87 | ** | 97 | 44 | 96 | ** | 44 | 44 | 34 | ** | 95 |
157 | 300 | 前后 | 14 | 34 | 26 | 15 | ** | 55 | ** | 55 | 55 | ** | 66 | 87 | 34 | 95 | ** | 99 | 86 | 98 | ** | 75 | 76 | 97 | ** | 96 |
158 | 300 | 前后 | 34 | 45 | 35 | 25 | ** | 36 | ** | 55 | 85 | ** | 76 | 97 | 45 | 96 | ** | 99 | 96 | 98 | ** | 75 | 95 | 77 | ** | 96 |
159 | 300 | 前后 | 02 | 02 | 05 | 04 | ** | 03 | ** | 03 | 33 | ** | 03 | 93 | 14 | 74 | ** | 89 | 45 | 88 | ** | 44 | 24 | 36 | ** | 95 |
160 | 300 | 前后 | 00 | 01 | 14 | 03 | ** | 02 | ** | 22 | 23 | ** | 02 | 84 | 03 | 75 | ** | 76 | 34 | 82 | ** | 25 | 24 | 46 | ** | 26 |
161 | 300 | 前后 | 00 | 01 | 03 | ** | 00 | 12 | ** | 00 | 00 | ** | 00 | 01 | 00 | 01 | ** | 11 | 01 | 05 | ** | 01 | 01 | 03 | ** | 02 |
实施例序号 | 剂量 | 施用时间 | TRZAW | HORVW | GOSHI | HELAN | ORYSA | GLXMA | BEAVA | ZEAMX | ALOMY | AVEFA | ECHCG | SETVI | GALAP | STEME | CHEAL | VERPE | LAMPU | VIOAR | SIDSP | AMBAR | ABUTH | IPOPU | SINAL | AMARE |
162 | 300 | 前后 | 00 | 00 | 03 | ** | 00 | 02 | ** | 00 | 00 | ** | 00 | 00 | 01 | 01 | ** | 01 | 05 | 05 | ** | 00 | 00 | 02 | ** | 00 |
163 | 300 | 前后 | 01 | 01 | 05 | ** | 00 | 04 | ** | 02 | 00 | ** | 00 | 32 | 12 | 03 | ** | 36 | 04 | 25 | ** | 03 | 02 | 24 | ** | 05 |
164 | 300 | 前后 | 00 | 01 | 06 | ** | 20 | 04 | ** | 03 | 01 | ** | 01 | 51 | 02 | 64 | ** | 46 | 15 | 76 | ** | 13 | 03 | 15 | ** | 38 |
165 | 300 | 前后 | 02 | 33 | 59 | ** | 20 | 26 | ** | 23 | 83 | ** | 82 | 95 | 48 | 96 | ** | 99 | 97 | 96 | ** | 86 | 47 | 69 | ** | 88 |
166 | 300 | 前后 | 01 | 12 | 45 | ** | 22 | 17 | ** | 12 | 53 | ** | 73 | 54 | 26 | 55 | ** | 88 | 75 | 87 | ** | 64 | 26 | 45 | ** | 88 |
167 | 300 | 前后 | 22 | 33 | 56 | ** | 45 | 26 | ** | 33 | 86 | ** | 86 | 98 | 25 | 87 | ** | 98 | 86 | 86 | ** | 84 | 46 | 95 | ** | 88 |
168 | 300 | 前后 | 22 | 33 | 48 | ** | 02 | 37 | ** | 12 | 74 | ** | 54 | 85 | 15 | 55 | ** | 99 | 68 | 98 | ** | 56 | 45 | 38 | ** | 97 |
169 | 300 | 前后 | 33 | 33 | 59 | ** | 55 | 26 | ** | 33 | 85 | ** | 65 | 96 | 15 | 94 | ** | 98 | 87 | 97 | ** | 55 | 46 | 66 | ** | 97 |
170 | 300 | 前后 | 00 | 01 | 04 | ** | 00 | 05 | ** | 01 | 00 | ** | 00 | 20 | 02 | 01 | ** | 03 | 13 | 55 | ** | 03 | 02 | 24 | ** | 65 |
171 | 300 | 前后 | 01 | 02 | 14 | ** | 00 | 04 | ** | 01 | 32 | ** | 22 | 63 | 04 | 02 | ** | 35 | 25 | 87 | ** | 04 | 04 | 14 | ** | 75 |
172 | 300 | 前后 | 01 | 01 | 02 | ** | ** | 02 | ** | 01 | 01 | ** | 02 | 02 | 03 | 04 | ** | 25 | 23 | 45 | ** | 12 | 02 | 06 | ** | 44 |
173 | 300 | 前后 | 12 | 33 | 66 | ** | ** | 27 | ** | 23 | 86 | ** | 86 | 97 | 66 | 87 | ** | 99 | 96 | 97 | ** | 86 | 56 | 88 | ** | 88 |
174 | 300 | 前后 | 32 | 33 | 56 | ** | 04 | 37 | ** | 23 | 85 | ** | 55 | 85 | 45 | 84 | ** | 99 | 87 | 98 | ** | 66 | 45 | 68 | ** | 97 |
175 | 300 | 前后 | 01 | 01 | 26 | ** | 01 | 17 | ** | 01 | 45 | ** | 15 | 75 | 05 | 24 | ** | 79 | 47 | 88 | ** | 16 | 05 | 08 | ** | 87 |
实施例序号 | 剂量 | 施用时间 | TRZAW | HORVW | GOSHI | HELAN | ORYSA | GLXMA | BEAVA | ZEAMX | ALOMY | AVEFA | ECHCG | SETVI | GALAP | STEME | CHEAL | VERPE | LAMPU | VIOAR | SIDSP | AMBAR | ABUTH | IPOPU | SINAL | AMARE |
176 | 400 | 前后 | 33 | 24 | ** | ** | 22 | 32 | ** | 22 | 74 | ** | ** | 86 | 38 | ** | ** | 98 | 87 | ** | ** | ** | 28 | 89 | ** | ** |
177 | 400 | 前后 | 73 | 55 | ** | ** | 54 | 46 | ** | 44 | 86 | ** | ** | 97 | 57 | ** | ** | 99 | ** | ** | ** | ** | 67 | 96 | ** | ** |
178 | 400 | 前后 | 21 | 23 | ** | ** | 24 | 14 | ** | 13 | 63 | ** | ** | 84 | 45 | ** | ** | 89 | ** | ** | ** | ** | 25 | 34 | ** | ** |
188 | 400 | 前后 | 43 | 54 | ** | ** | 63 | 45 | ** | 53 | 97 | ** | ** | 98 | 89 | ** | ** | 99 | 98 | ** | ** | ** | 98 | 99 | ** | ** |
190 | 400 | 前后 | 54 | 65 | ** | ** | 54 | 57 | ** | 53 | 98 | ** | ** | 99 | 99 | ** | ** | 99 | 98 | ** | ** | ** | 99 | 99 | ** | ** |
191 | 400 | 前后 | 44 | 44 | ** | ** | 54 | 57 | ** | 43 | 98 | ** | ** | 98 | 89 | ** | ** | 99 | 98 | ** | ** | ** | 99 | 99 | ** | ** |
192 | 400 | 前后 | 43 | 44 | ** | ** | 33 | 56 | ** | 42 | 87 | ** | ** | 98 | 79 | ** | ** | 99 | 88 | ** | ** | ** | 99 | 99 | ** | ** |
193 | 400 | 前后 | 44 | 54 | ** | ** | 34 | 45 | ** | 43 | 88 | ** | ** | 99 | 78 | ** | ** | 98 | 87 | ** | ** | ** | 88 | 99 | ** | ** |
Claims (9)
2.根据权利要求1所述的化合物,其特征是它选自下列化合物组成的组:
2-(2′,4′-二氟苯基)-6-甲基-4-(1″-甲基-3″-三氟甲基吡唑-5-基氧基)嘧啶,
2-(2′,4′-二氟苯基)-6-甲基-4-(3″-三氟甲基苯氧基)嘧啶,
2-(3′-氯苯基)-5-甲基-4-(1″-甲基-3″-三氟甲基吡唑-5-基氧基)嘧啶,
2-(3′-氯苯基)-5-甲基-4-(3″-三氟甲基苯氧基)嘧啶,
2-(4′-氟苯基)-6-甲基-4-(3″-三氟甲基苯氧基)嘧啶,
2-(4′-氟苯基)-4-(1″-甲基-3″-三氟甲基吡唑-5-基氧基)-5-甲基嘧啶,
2-(4′-氟苯基)-4-(1″-甲基-3″-三氟甲基吡唑-5-基氧基)-6-甲基嘧啶,
4-(2″-氯吡啶-4″-基氧基)-2-(2′,4′-二氟苯基)-5-甲基嘧啶,
4-(2″-氯吡啶-4″-基氧基)-5,6-二甲基-2-(4′-三氟甲氧基苯基)嘧啶,
4-(2″-氯吡啶-4″-基氧基)-5,6-二甲基-2-(4′-三氟甲基苯基)嘧啶,
4-(2″-氯吡啶-4″-基氧基)-5-甲基-2-(4′-三氟甲氧基苯基)嘧啶,
4-(2″-氯吡啶-4″-基氧基)-5-甲基-2-(4′-三氟甲基苯基)嘧啶,
4-(2″-氯吡啶-4″-基氧基)-6-甲基-2-(4′-三氟甲氧基苯基)嘧啶,
4-(2″-氯吡啶-4″-基氧基)-6-甲基-2-(4′-三氟甲基苯基)嘧啶,
5,6-二甲基-2-(4′-三氟甲氧基苯基)-4-(1″-甲基-3″-三氟甲基吡唑-5″-基氧基)嘧啶,
5,6-二甲基-2-(4′-三氟甲氧基苯基)-4-(3″-三氟甲基苯氧基)嘧啶,
5,6-二甲基-2-(4′-三氟甲基苯基)-4-(3″-三氟甲基苯氧基)嘧啶,
5,6-二甲基-4-(1″-甲基-3″-三氟甲基吡唑-5″-基氧基)-2-(4′-三氟甲基苯基)嘧啶,
5-甲基-2-(3′-甲基苯基)-4-(1″-甲基-3″-三氟甲基吡唑-5″-基氧基)嘧啶,
5-甲基-2-(3′-甲基苯基)-4-(3″-三氟甲基苯氧基)嘧啶,
5-甲基-2-(4′-三氟甲氧基苯基)-4-(1″-甲基-3″-三氟甲基吡唑-5″-基氧基)嘧啶,
5-甲基-2-(4′-三氟甲氧基苯基)-4-(3″-三氟甲基苯氧基)嘧啶,
5-甲基-2-(4′-三氟甲基苯基)-4-(1″-甲基-3″-三氟甲基吡唑-5″-基氧基)嘧啶,
5-甲基-4-(3″-三氟甲基苯氧基)-2-(4′-三氟甲基苯基)嘧啶,
6-甲基-2-(4′-三氟甲氧基苯基)-4-(1″-甲基-3″-三氟甲基吡唑-5″-基氧基)嘧啶,
6-甲基-2-(4′-三氟甲氧基苯基)-4-(3″-三氟甲基苯氧基)嘧啶,
6-甲基-4-(3″-三氟甲基苯氧基)-2-(4′-三氟甲基苯基)嘧啶,
6-甲基-2-(4′-三氟甲基苯基)-4-(1″-甲基-3″-五氟乙基吡唑-5″-基氧基)嘧啶,
6-甲基-2-(4′-氰基苯基)-4-(1″-甲基-3″-五氟乙基吡唑-5″-基氧基)嘧啶,
6-甲氧基-2-(4′-氰基苯基)-4-(1″-甲基-3″-五氟乙基吡唑-5″-基氧基)嘧啶,
6-甲基-4-(2″,2″-二氟-1″,3″-苯并间二氧杂环戊烯-4″-基)-2-(4′-三氟甲基苯基)嘧啶,
6-乙基-2-(4′-三氟甲基苯基)-4-(1″-甲基-3″-三氟甲基吡唑-5″-基氧基)嘧啶,
6-乙基-2-(4′-三氟甲基苯基)-4-(3″-三氟甲基苯氧基)嘧啶,
6-甲基-2-(4′-三氟磺酰苯基)-4-(1″-甲基-3″-五氟乙基吡唑-5″-基氧基)嘧啶,
6-乙基-2-(4′-三氟甲基苯基)-4-(2′-氯吡啶-4′-基氧基)嘧啶,
6-炔丙基-2-(4′-三氟甲基苯基)-4-(1″-甲基-3″-三氟甲基吡唑-5″-基氧基)嘧啶,
6-甲氧基甲基-2-(4′-氯苯基)-4-(1″-甲基-3″-三氟甲基吡唑-5″-基氧基)嘧啶,
6-甲氧基甲基-2-(4′-氯苯基)-4-(3″-三氟甲基苯氧基)嘧啶,
4-(3″-三氟甲基苯氧基)-2-(4′-三氟甲基苯基)嘧啶,
4-(1″-甲基-3″-三氟甲基吡唑-5″-基氧基)-2-(4′-三氟甲基苯基)嘧啶,
6-氯-2-(4′-三氟甲基苯基)-4-(1″-甲基-3″-三氟甲基吡唑-5″-基氧基)嘧啶,
6-溴-2-(4′-三氟甲基苯基)-4-(1″-甲基-3″-三氟甲基吡唑-5″-基氧基)嘧啶,
6-氯-2-(4′-氯甲基苯基)-4-(1″-甲基-3″-三氟甲基吡唑-5″-基氧基)嘧啶,
6-氟-2-(4′-三氟甲基苯基)-4-(1″-甲基-3″-三氟甲基吡唑-5″-基氧基)嘧啶,
6-甲氧基-2-(4′-三氟甲基苯基)-4-(3″-三氟甲基苯氧基)嘧啶,
6-甲氧基-2-(4′-三氟甲基苯基)-4-(1″-甲基-3″-三氟甲基吡唑-5″-基氧基)嘧啶,
6-甲氧基-2-(4′-三氟甲基苯基)-4-(2′-氯吡啶-4′-基氧基)嘧啶,
5-甲氧基-2-(4′-三氟甲基苯基)-4-(3″-三氟甲基苯氧基)嘧啶,
5-甲氧基-2-(4′-三氟甲基苯基)-4-(1″-甲基-3″-三氟甲基吡唑-5″-基氧基)嘧啶,
5-甲氧基-2-(4′-三氟甲基苯基)-4-(2′-氯吡啶-4′-基氧基)嘧啶,
6-乙氨基-2-(4′-三氟甲基苯基)-4-(1″-甲基-3″-三氟甲基吡唑-5″-基氧基)嘧啶,
6-甲氧基氨基-2-(4′-氯苯基)-4-(1″-甲基-3″-三氟甲基吡唑-5″-基氧基)嘧啶,
6-乙烯基-2-(4′-三氟甲基苯基)-4-(1″-甲基-3″-三氟甲基吡唑-5″-基氧基)嘧啶。
4.一种通式(XV)的化合物,其中A、R2、和m的定义如权利要求1所述:
6.一种制备通式(XV)的化合物的方法,
其中A、m和R2的定义与权利要求1的相同,该方法包括使通式III的化合物
其中Z是氮,R1是卤素,其在嘧啶环的6-位,n是1,R2和m的定义与权利要求1中的相同,与2当量的通式IV化合物:A-XM反应,其中A,X的定义与权利要求1的相同,M代表金属原子。
7.一种除草组合物,包括至少一种如权利要求1-4任一所述的化合物和载体和/或表面活性剂。
8.一种在施用地抑制不需要植物的生长的方法,包括用有效量的如权利要求1-4任一所述的至少一种的化合物处理施用地。
9.有效量的如权利要求1-4任一所述的化合物在抑制不需要植物的生长中的用途。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP95101057.8 | 1995-01-26 | ||
EP95101057 | 1995-01-26 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1143078A CN1143078A (zh) | 1997-02-19 |
CN1135227C true CN1135227C (zh) | 2004-01-21 |
Family
ID=8218937
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB961025476A Expired - Fee Related CN1135227C (zh) | 1995-01-26 | 1996-01-26 | 除草的2,6-二取代吡啶和2,4-二取代嘧啶 |
Country Status (20)
Country | Link |
---|---|
US (1) | US5824624A (zh) |
JP (1) | JP4049405B2 (zh) |
KR (1) | KR100497135B1 (zh) |
CN (1) | CN1135227C (zh) |
AR (1) | AR000795A1 (zh) |
AT (1) | ATE236124T1 (zh) |
AU (1) | AU710816B2 (zh) |
BR (1) | BR9600222A (zh) |
CA (1) | CA2167982A1 (zh) |
CZ (1) | CZ290330B6 (zh) |
DE (1) | DE69627062T2 (zh) |
HU (1) | HU221864B1 (zh) |
IL (1) | IL116855A (zh) |
MX (1) | MX9600347A (zh) |
RU (1) | RU2134261C1 (zh) |
SK (1) | SK284993B6 (zh) |
TR (1) | TR199600065A2 (zh) |
TW (1) | TW321639B (zh) |
UA (1) | UA48112C2 (zh) |
ZA (1) | ZA96529B (zh) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5972842A (en) * | 1996-12-12 | 1999-10-26 | American Cyanamid Company | Herbicidal cyanopyridines |
US6310006B1 (en) | 1997-05-30 | 2001-10-30 | American Cyanamid Company | Herbicidal 3,5-difluoropyridines |
DE69837999T2 (de) * | 1997-11-07 | 2007-10-25 | Basf Ag | Herbizide furanyl- und thienyloxyazine |
AU780907B2 (en) * | 1999-04-15 | 2005-04-21 | Basf Aktiengesellschaft | Process for the preparation of substituted pyrimidines |
US6281358B1 (en) | 1999-04-15 | 2001-08-28 | American Cyanamid Company | Process for the preparation of substituted pyrimidines |
CN1278607C (zh) | 1999-11-17 | 2006-10-11 | 拜尔公司 | 基于2,6-二取代的吡啶衍生物的选择性除草剂 |
AR029489A1 (es) * | 2000-03-10 | 2003-07-02 | Euro Celtique Sa | Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento |
ATE356812T1 (de) | 2000-05-19 | 2007-04-15 | Basf Ag | Methode zur bekämpfung unerwünschten pflanzenwuchses in getreide |
US6894003B2 (en) | 2000-06-23 | 2005-05-17 | Basf Aktiengesellschaft | Enhancement of the activity of carotenoid biosynthesis inhibitor herbicides |
AR037233A1 (es) | 2001-09-07 | 2004-11-03 | Euro Celtique Sa | Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento |
WO2005047268A2 (en) * | 2003-11-10 | 2005-05-26 | X-Ceptor Therapeutics, Inc. | Substituted pyrimidine compositions and methods of use |
AU2006311910A1 (en) * | 2005-11-03 | 2007-05-18 | Irm Llc | Protein kinase inhibitors |
CN102066336B (zh) * | 2008-04-18 | 2014-02-19 | 陶氏益农公司 | 2-(取代的苯基)-6-羟基或烷氧基-5-取代的-嘧啶-4-羧酸酯和它们作为除草剂的用途 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4405743A (en) * | 1979-08-31 | 1983-09-20 | Hokko Chemical Industry Co., Ltd. | Pyrazolylpyrimidine derivatives |
US4366189A (en) * | 1979-12-21 | 1982-12-28 | Ciba-Geigy Corporation | 4-Heterocyclyl-4'-vinylstilbenes |
DOP1981004033A (es) * | 1980-12-23 | 1990-12-29 | Ciba Geigy Ag | Procedimiento para proteger plantas de cultivo de la accion fitotoxica de herbicidas. |
JPS63107966A (ja) * | 1986-05-22 | 1988-05-12 | Fujisawa Pharmaceut Co Ltd | ピリミジン誘導体 |
US4849011A (en) * | 1986-09-16 | 1989-07-18 | Sumitomo Chemical Company, Ltd. | 4-substituted-2,6-diphenylpyridine compounds and herbicide containing the same as an active ingredient |
JP2639049B2 (ja) * | 1988-07-08 | 1997-08-06 | 住友化学工業株式会社 | ピリジルピリミジン誘導体およびそれを有効成分とする農園芸用殺菌剤 |
ES2059770T3 (es) * | 1988-08-09 | 1994-11-16 | Sumitomo Chemical Co | Derivados de 2,4-difenilpirimidina 5-substituidos, su produccion y su utilizacion herbicida. |
AU631017B2 (en) * | 1989-10-23 | 1992-11-12 | Sumitomo Chemical Company, Limited | 5-substituted-2,4-diphenylpyrimidine derivatives, their production and use |
DE4029654A1 (de) * | 1990-09-19 | 1992-04-02 | Hoechst Ag | 2-phenyl-pyrimidine, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als fungizide |
TW231258B (zh) * | 1992-05-27 | 1994-10-01 | Shell Internat Res Schappej B V | |
TW234077B (zh) * | 1992-07-17 | 1994-11-11 | Shell Internat Res Schappej B V | |
EP0723960B1 (en) * | 1995-01-26 | 2003-04-02 | Basf Aktiengesellschaft | Herbicidal 2,6-disubstituted pyridines and 2,4-disubstituted pyrimidines |
-
1996
- 1996-01-19 CZ CZ1996175A patent/CZ290330B6/cs not_active IP Right Cessation
- 1996-01-22 IL IL11685596A patent/IL116855A/xx not_active IP Right Cessation
- 1996-01-23 AT AT96300454T patent/ATE236124T1/de not_active IP Right Cessation
- 1996-01-23 ZA ZA96529A patent/ZA96529B/xx unknown
- 1996-01-23 DE DE69627062T patent/DE69627062T2/de not_active Expired - Fee Related
- 1996-01-23 UA UA96010278A patent/UA48112C2/uk unknown
- 1996-01-24 AR ARP960101141A patent/AR000795A1/es active IP Right Grant
- 1996-01-24 AU AU42164/96A patent/AU710816B2/en not_active Ceased
- 1996-01-24 CA CA002167982A patent/CA2167982A1/en not_active Abandoned
- 1996-01-24 MX MX9600347A patent/MX9600347A/es not_active IP Right Cessation
- 1996-01-25 KR KR1019960001585A patent/KR100497135B1/ko not_active IP Right Cessation
- 1996-01-25 RU RU96101815A patent/RU2134261C1/ru not_active IP Right Cessation
- 1996-01-25 JP JP03010196A patent/JP4049405B2/ja not_active Expired - Fee Related
- 1996-01-25 BR BR9600222A patent/BR9600222A/pt not_active IP Right Cessation
- 1996-01-25 HU HU9600161A patent/HU221864B1/hu not_active IP Right Cessation
- 1996-01-25 SK SK109-96A patent/SK284993B6/sk unknown
- 1996-01-26 TR TR96/00065A patent/TR199600065A2/xx unknown
- 1996-01-26 CN CNB961025476A patent/CN1135227C/zh not_active Expired - Fee Related
- 1996-04-09 TW TW085104165A patent/TW321639B/zh active
- 1996-12-06 US US08/761,479 patent/US5824624A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
TW321639B (zh) | 1997-12-01 |
MX9600347A (es) | 1997-01-31 |
TR199600065A2 (tr) | 1996-08-21 |
AR000795A1 (es) | 1997-08-06 |
SK10996A3 (en) | 1997-09-10 |
JP4049405B2 (ja) | 2008-02-20 |
KR100497135B1 (ko) | 2005-11-16 |
BR9600222A (pt) | 1998-01-06 |
HUP9600161A2 (en) | 1997-02-28 |
AU4216496A (en) | 1996-08-01 |
HUP9600161A3 (en) | 1997-08-28 |
ATE236124T1 (de) | 2003-04-15 |
US5824624A (en) | 1998-10-20 |
UA48112C2 (uk) | 2002-08-15 |
CZ290330B6 (cs) | 2002-07-17 |
JPH08277268A (ja) | 1996-10-22 |
IL116855A0 (en) | 1996-07-23 |
CA2167982A1 (en) | 1996-07-27 |
IL116855A (en) | 2001-01-11 |
DE69627062T2 (de) | 2003-11-06 |
RU2134261C1 (ru) | 1999-08-10 |
HU9600161D0 (en) | 1996-03-28 |
KR960029330A (ko) | 1996-08-17 |
CN1143078A (zh) | 1997-02-19 |
DE69627062D1 (de) | 2003-05-08 |
ZA96529B (en) | 1997-07-23 |
SK284993B6 (sk) | 2006-04-06 |
CZ17596A3 (en) | 1996-08-14 |
AU710816B2 (en) | 1999-09-30 |
HU221864B1 (hu) | 2003-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1135227C (zh) | 除草的2,6-二取代吡啶和2,4-二取代嘧啶 | |
CN1083433C (zh) | 2,6-二取代的吡啶类,它们的制备方法,除草组合物和用途 | |
CN1117748C (zh) | 2,6-双取代的吡啶和2,4-双取代的嘧啶除草剂 | |
CN1087085A (zh) | 杀虫化合物 | |
EP0723960B1 (en) | Herbicidal 2,6-disubstituted pyridines and 2,4-disubstituted pyrimidines | |
CN1054974A (zh) | 除草用的甲酰胺衍生物 | |
JPS6250466B2 (zh) | ||
US5532367A (en) | Insecticidal pteridines and 8-deazapteridines | |
WO1991013065A1 (en) | 6-aryl-2-substituted benzoic acid herbicides | |
CN1080637A (zh) | 吡啶衍生物及其制备方法,含此衍生物的除草剂组合物及其除草方法 | |
US5521192A (en) | Insecticidal 5-substituted-2,4-diaminopyrimidine derivatives | |
CN86106435A (zh) | 咪唑啉基衍生物,其制备方法和含有这类化合物的具有除草作用的制剂 | |
HU205832B (en) | Herbicide compositions containing 5-substituted-2-/2-imidazolin-2-yl/-nicotinic acid derivative and process for producing these compounds | |
CN1037705A (zh) | 新的嘧啶酮衍生物的制备方法 | |
Simkovsky et al. | Some regioselective cross-coupling reactions of halopyridines and halopyrimidines | |
CN1071425A (zh) | 具有除草活性的吡啶酰胺衍生物 | |
EP1028959B1 (en) | Herbicidal furanyl- and thienyloxyazines | |
EP0694538A2 (en) | 2-benzyloxy-4-phenoxypyrimidine derivative, processes for producing the derivative and herbicidal composition containing the derivative | |
EP0692477A1 (en) | Herbicidal compositions containing 2-benzyloxypyrimidine derivatives | |
US6066597A (en) | Herbicidal 2-(hetero)aryloxy-6-arylpyridines and 2-aryl-4-(hetero)aryloxy-6-arylpyridines and 2-aryl-4-(hetero)aryloxypyrimidines | |
AU730571B2 (en) | Herbicidal 2,6-disubstituted pyridines and 2,4-disubstituted pyrimidines | |
CN1040754C (zh) | 3-(取代的酮和醇)-2-(2-咪唑啉-2-基)吡啶和喹啉、制备方法和除草剂 | |
JPH0559015A (ja) | ピリミジン誘導体及び該誘導体を有効成分とする除草剤 | |
MXPA97006048A (en) | 2.4-disustitute pyrimidines and 2,6-disused pirimidines herbici | |
CZ290340B6 (cs) | Pyrimidinové deriváty |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |